TRex Bio, Inc.

S-1 filed

TRex Bio, Inc. is seeking to raise capital through an IPO, focusing on the development of its two lead product candidates, TRB-061 and TRB-071, for neurodegenerative diseases. The filing highlights significant risks in clinical development, including high failure rates, regulatory uncertainties, and financial challenges. The company emphasizes its reliance on successful clinical trials and regulatory approvals, with no current collaboration revenue compared to prior periods. Operational risks include delays in patient enrollment, manufacturing issues, and dependence on third-party contractors. The filing underscores the need for continued funding to advance its pipeline.

DRS/A amended

DRS/A amended

TRex Bio, Inc. reported collaboration revenue of $39.1 million in 2024 under the Lilly Collaboration Agreement, which declined to $0 in 2025 after the combined performance obligation was fully satisfied. Research and development expenses decreased to $29.8 million in 2025 from $35.0 million in 2024, driven by reduced external costs for TRB-061 and lower headcount, though preclinical pipeline costs increased. General and administrative expenses rose to $8.0 million in 2025. The company faces significant risks including uncertain product development, potential limitations on net operating loss carryforwards due to ownership changes, and reliance on collaboration revenue. Liquidity remains a concern, with $67.7 million in cash and marketable securities as of December 2025, but continued fundraising is anticipated.

DRS filed

TRex Bio, Inc. reports ongoing financial challenges with significant research and development (R&D) expenses driving operating losses. The company relies heavily on collaboration revenue, such as the Lilly Collaboration Agreement, but recorded no revenue in 2025. R&D costs decreased in 2025 due to completed manufacturing activities for TRB-061, though other product candidates saw increased expenses. The firm faces uncertainty in clinical development, regulatory approvals, and future funding needs, with no prior IPO filings to reference. Liquidity remains constrained, requiring continued capital raises to sustain operations.